The earnings report is a routine update with no material surprise. The key catalyst remains the proof-of-concept data from the ASCEND trial expected in Q1 2027. Monitor for CR-002 IND filing in H2 2026. The recent offering provides a long cash runway but dilutes existing shareholders by ~30%.
Price Chart
Executive Summary
Crescent Biopharma reported Q2 2026 financial results with net loss of $24.8M ($0.74 per share) vs $21.8M in Q2 2025. The company had no product revenue and R&D expenses rose to $19.4M as pipeline trials progress. Cash was $171.6M at quarter-end, pro forma $305.1M after the July 2026 public offering, extending runway into H2 2028. Pipeline milestones remain on track with multiple clinical data readouts expected beginning Q1 2027.
Key Financial Metrics
Key Facts
- Net loss of $24.8M for Q2 2026 compared to $21.8M in Q2 2025
- Cash and cash equivalents of $171.6M as of June 30, 2026; pro forma $305.1M after July offering
- Completed $143.7M public offering of ordinary shares and pre-funded warrants in July 2026
- R&D expenses increased to $19.4M from $12.1M year-over-year to support pipeline development
- ASCEND Phase 1/2 trial of CR-001 enrollment progressing; proof-of-concept data expected Q1 2027
- CR-001 + sac-TMT Phase 2 trial in NSCLC initiated in China by Kelun-Biotech
- CR-003 Phase 1/2 trial ongoing in China; CR-002 IND on track for H2 2026
- Pro forma shares outstanding of 43.5M as of June 30, 2026, reflecting the July offering
Financial Impact
No revenue from product sales; net loss of $24.8M in the quarter; cash burn rate indicates need for the recent $143.7M offering to fund operations into H2 2028
Risk Factors
- No approved products or revenue; clinical trial failure risk
- Significant dilution from July 2026 offering (9.9M shares/equivalents added)
- Cash burn increased as R&D expenses rise; ability to raise additional capital if needed
- Competitive landscape for PD-1 x VEGF bispecific antibodies and ADCs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-050805 |
| Document: cbio-20260730.htm | 0001628280-26-050805 |
| Document: 0001628280-26-050805-index-headers.html | 0001628280-26-050805 |
| Document: 0001628280-26-050805-index.html | 0001628280-26-050805 |
| Document: 0001628280-26-050805.txt | 0001628280-26-050805 |
| 8-K Data (Synthetic) | 0001628280-26-050805 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 8-K | $11.84 | awaiting T+60 | — | $13.27 (+12.08%) |
Oct 15, 2026 12d ago | Press Release | $11.84 | awaiting T+60 | — | $13.27 (+12.08%) |
Oct 5, 2026 22d ago | Press Release | $13.94 | awaiting T+60 | — | $13.27 (−4.81%) |
Sep 18, 2026 5w ago | Insider Cluster | $16.25 | awaiting T+60 | — | $13.27 (−18.34%) |
Jul 30, 2026 12w ago | 8-K | $15.02 $12.82 | ▼ −14.65% | ▼ −17.11% | $13.27 (−11.65%) |
Jul 20, 2026 14w ago | Insider Buy | $16.64 $12.91 | ▼ −22.42% | ▼ −26.39% | $13.27 (−20.25%) |
Jul 15, 2026 14w ago | 8-K / 424B5 | $15.11 $14.91 | ▲ +1.32% | ▲ +5.03% | $13.27 (+12.18%) |
Jul 14, 2026 14w ago | Press Release | $15.67 $14.12 | ▲ +9.89% | ▲ +12.42% | $13.27 (+15.32%) |
Jul 14, 2026 15w ago | 424B5 | $15.67 $14.12 | ▲ +9.89% | ▲ +12.42% | $13.27 (+15.32%) |
Jul 13, 2026 15w ago | EFFECT | $15.69 $13.57 | ▼ −13.51% | ▼ −17.51% | $13.27 (−15.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers